New IQVIA Analysis Finds People with Diabetes Bear Disproportionate Share of 340B-Related Costs

Study supported by the Diabetes Leadership Council estimates 340B displaced $4.8 billion in commercial drug rebates and added $156 million in out-of-pocket costs for people with diabetes in 2025

FOR IMMEDIATE RELEASE

WASHINGTON, D.C. (October 8, 2026) — A new analysis from IQVIA, 'The Cost of 340B to People with Diabetes,' finds that commercially insured people with diabetes and their health plans bear a disproportionate share of costs associated with the federal 340B Drug Pricing Program. The findings raise questions about how 340B affects patients with chronic conditions and the employers that provide their health coverage, and points to the need for greater transparency into the program.

The white paper was supported by the Diabetes Leadership Council (DLC), which helped ensure its findings were considered through the lens of people living with diabetes.

The Cost of 340B to People with Diabetes estimates that in 2025, commercial health plans and self-insured employers spent an additional $4.8 billion on medications for diabetes patients because the 340B program prevented them from receiving negotiated drug rebates. The analysis also estimates that diabetes patients with commercial insurance paid $156 million in 340B-related out-of-pocket upcharges, which can occur when a patient's cost sharing exceeds the discounted price a 340B provider paid for the medication.

"People with diabetes already face significant and unavoidable costs to manage a lifelong condition, and they should not be disproportionately absorbing additional costs from a program designed to strengthen the health care safety net," said George Huntley, CEO of the Diabetes Patient Advocacy Coalition (DPAC). "This analysis reinforces the need for greater transparency and accountability around 340B so patients, employers and policymakers can better understand where costs are going and whether the program's benefits are reaching the people it was intended to help."

The full IQVIA white paper, The Cost of 340B to People with Diabetes, is available here.

About the Diabetes Leadership Council
The Diabetes Leadership Council (DLC) is a 501(c)(3) patient advocacy organization comprised of experienced leaders in the diabetes community. Our members - all former leaders of national diabetes organizations - are committed to securing effective, affordable health care and a discrimination-free environment for every person affected by diabetes through sound policy initiatives at the federal and state levels. EIN #46-3571905.

Media Contact:
CURA.DPAC@curastrategies.com